Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

5Total

P 1 (1)

P 2 (2)

P 3 (1)

P 4 (1)

Trial Status

Completed4

Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (5)

Showing 5 of 5 trials

NCT05770609Phase 2CompletedPrimary

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

NCT01201122Phase 4CompletedPrimary

Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis

NCT01033305Phase 2CompletedPrimary

Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)

NCT01039597Phase 1UnknownPrimary

Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis

NCT01045018Phase 3CompletedPrimary

A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis

Showing all 5 trials

Mild to Moderate Ulcerative Colitis